NASDAQ:CRBP - Corbus Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.86 -0.14 (-1.75 %)
(As of 01/17/2019 09:41 AM ET)
Previous Close$8.00
Today's Range$7.81 - $8.16
52-Week Range$4.50 - $9.95
Volume550,845 shs
Average Volume1.04 million shs
Market Capitalization$457.90 million
P/E Ratio-12.09
Dividend YieldN/A
Beta2.11
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in December 2013 and is headquartered in Norwood, MA.

Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRBP
CUSIPN/A
Phone617-963-0100

Debt

Current Ratio3.45
Quick Ratio3.45

Price-To-Earnings

Sales & Book Value

Annual Sales$2.44 million
Price / Sales184.39
Price / Cash FlowN/A
Book Value$1.04 per share
Price / Book7.56

Profitability

Net Income$-32,420,000.00
Net MarginsN/A
Return on Assets-71.21%

Miscellaneous

Employees47
Market Cap$457.90 million
OptionableOptionable

Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) announced its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.05. The biopharmaceutical company earned $1.09 million during the quarter, compared to the consensus estimate of $1.66 million. View Corbus Pharmaceuticals' Earnings History.

When is Corbus Pharmaceuticals' next earnings date?

Corbus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Corbus Pharmaceuticals.

What price target have analysts set for CRBP?

6 equities research analysts have issued 1-year price targets for Corbus Pharmaceuticals' stock. Their predictions range from $22.00 to $38.00. On average, they anticipate Corbus Pharmaceuticals' share price to reach $26.20 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price. View Analyst Price Targets for Corbus Pharmaceuticals.

What is the consensus analysts' recommendation for Corbus Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corbus Pharmaceuticals.

Has Corbus Pharmaceuticals been receiving favorable news coverage?

Press coverage about CRBP stock has trended somewhat negative on Thursday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Corbus Pharmaceuticals earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Corbus Pharmaceuticals' key competitors?

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the folowing people:
  • Yuval Cohen, Chief Executive Officer & Director
  • Mark A. Tepper, President & Chief Scientific Officer
  • Sean F. Moran, CFO & Principal Accounting Officer
  • Barbara White, Chief Medical Officer
  • Robert Discordia, VP-Pharmaceutical Development & Manufacturing

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $7.86.

How big of a company is Corbus Pharmaceuticals?

Corbus Pharmaceuticals has a market capitalization of $457.90 million and generates $2.44 million in revenue each year. The biopharmaceutical company earns $-32,420,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Corbus Pharmaceuticals employs 47 workers across the globe.

What is Corbus Pharmaceuticals' official website?

The official website for Corbus Pharmaceuticals is http://www.corbuspharma.com.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]


MarketBeat Community Rating for Corbus Pharmaceuticals (NASDAQ CRBP)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  421
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2019 by MarketBeat.com Staff

Featured Article: Google Finance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel